• 站内搜索:


2005-11-21 14:32 新航道学校 

  Part B


  The following paragraphs are given in a wrong order. For Questions 41-45, you are required to reorganize these paragraphs into a coherent article by choosing from the list A-E to fill in each numbered box. The first and the last paragraphs have been placed for you in boxes. Mark your answers on ANSWER SHEET 1. (10 points)

  [A]The rise of a tycoon who is fond of America and South Africa, and who prints English slogans on his bottles of milk and mineral water, is a snub to Mr Ratsiraka. The president, who has dominated politics since 1975——with a few years' absence in the mid-1990s——steers close to France, the former colonial power. He has been unwell, and spends much of his time having medical treatment in Paris. His government, predictably, is accused of widespread corruption.But he offers stability——and declares that "any other president" would usher in years of uncertainty.

  [B]Mr Ratsiraka might indeed feel aggrieved if he did lose power just as the economy is coming right. After a two-decade spell as a socialist, then a few years of exile, he bounced back into the presidency in 1996 to impose austere neo-liberal reforms. These are now paying off. Many people are still desperately badly off, living in villages without roads, electricity or doctors. But, according to an optimistic IMF report on December 13th, the economy may turn out to have enjoyed 6.7% growth this year and inflation is low.

  [C]In a high turnout, he took nearly 80% of the votes in the capital, and well over half in other cities. Results from the less susceptible countryside are slowly coming in. They narrow the gap, but he still seems to have a chance of either beating the incumbent, Didier Ratsiraka, outright or facing him in a run-off next year.

  [D]A swelling flow of tourists comes to the island to see its rainforests, lemurs and tropical beaches. Sales of textiles to America are doing well, thanks to tariff reductions there. And, in the past few years, Asian investors have opened dozens of factories in special export zones around the capital. Mr Ratsiraka has managed to negotiate debt relief that almost halves the amount the country spends on servicing its debts.It is thus able to spend a bit more on schools and hospitals. Incomes in the cities are clearly up. A good rice harvest this year, and the absence of cyclones, has eased hunger in the countryside.

  [E]As mayor, Mr Ravalomanana won many citizens' hearts by cleaning up the capital, and seeing to new roads and street lighting. He oversaw a building boom, the rise of a dozen flashy new supermarkets, more policemen on the streets and a cut in crime. He is known in the country at large, too, thanks to his Tiko food empire, which delivers yoghurt and other good things to Madagascar's emerging middle class. His face is everywhere on T-shirts, baseball caps and bags——all part of a slick campaign that was helped along by his own radio and television stations.His Christian fervour, and his job on a council of Protestant churches, have also helped him, especially among the rural poor.

  [F]All this is rare good news for Africa. Might it be risked if there were a change of president? Some point to possible ethnic tension: Mr Ravalomanana is from the highland Imerina people, who have a mix of Asian-settler and African blood, who have never before held political office over the blacker coastal communities. Others worry that he will have little support in parliament, and that his business career has not prepared him for political compromises. A bigger concern, perhaps, is that he might not seriously undertake to spread the good times enjoyed in the capital into the impoverished countryside.

  [G]EXCITEMENT is in the air in Madagascar, a vast island of 15m people off the east coast of Africa. On December 16th its voters trudged to the polls from their homes in highland towns and remote forest villages to pick a president. Many favoured Marc Ravalomanana, a tycoon who is also the handsome young mayor of the capital, Antananarivo.



  Part C


  Read the following text carefully and then translate the underlined segments into Chinese. Your translation should be written clearly on ANSWER SHEET 2. (10points)

  Biotech firms are no longer mere fodder for the pharmaceutical giants

  AMGEN, the world's biggest biotechnology company, made its fortune from a drug that fortifies the blood of patients who are undergoing dialysis. On December 17th, the California company acquired some new blood of its own with the purchase of Immunex, a Seattle-based biotechnology company, for $16 billion.

  This deal, a biotech-industry record, gives Amgen a firm footing in the multibillion-dollar market in inflammation control. Immunex's most lucrative product is Enbrel, a treatment for rheumatoid arthritis.(46) Amgen hopes to triple the drug's sales to more than $3 billion by 2005, widening its use to other diseases, such as psoriasis, and overcoming manufacturing constraints that have kept the drug in short supply.

  With this takeover, Immunex passes from one parent to another. American Home Products (AHP) holds 41% of the shares, and has given the firm sales and marketing support. (47)But AHP has been selling down its stake since last year, in part to finance a $3.8 billion settlement of claims against its diet drugs.

  (48)Although Amgen calls itself a biotech company, its market capitalisation of around $62 billion makes it larger than Pharmacia and several other well-known mainstream drug companies, traditionally considered the big brothers of biotech. But Amgen likes to think of itself as less bureaucratic and more entrepreneurial than its pharmaceutical brethren, and it is free of such big-pharma woes as imminent patent expiry. (49)However, as Joseph Dougherty, a biotech analyst at Lehman Brothers, points out, Amgen will find it hard to retain the freedom of its nimble youth as it strives to expand its sales by more than 30% a year.

  Historically, pharmaceutical companies have used their deep pockets to buy biotech companies. Now, increasingly, biotech companies are buying each other (see chart). Such industry consolidation is driven by strategy rather than desperation, according to Scott Morrison, a consultant with Ernst & Young. (50)Companies are pooling their resources to build scale in research and development, and in sales, or to fill holes in their product pipelines, as Amgen has just done. With almost 1,400 biotech companies in America, and a comparable number in Europe, there is plenty of room for more togetherness.